*Refresh the page if the below document does not appear.
The generics company Sandoz spun off by Novartis
A 100% spin-off of Sandoz would result in the creation of the top European generics company, a world leader in biosimilars, and a more narrowly focused Novartis. This separation would be in the best interests of shareholders, according to the Sandoz strategic review.
Bayer unveils a medication for chronic kidney disease
Bayer announced that it has launched Kerendia, a medication for the treatment of chronic kidney disease associated with diabetes. The medication is recommended for people with type 2 diabetes and chronic kidney disease.
Key diabetes medications subject to price restrictions set by the pricing authority
Two important anti-diabetic medications, Linagliptin and Sitagliptin, have fixed prices set by India’s drug pricing authority. The National Pharmaceutical Pricing Authority has set retail prices for 45 drug formulations, including the two anti-diabetic medications.
USFDA approved Aurobindo Pharma's contraceptive
USFDA has given final approval to Aurobindo Pharma Limited’s wholly-owned subsidiary, Eugia Pharma Specialties Limited, to manufacture and market Medroxyprogesterone Acetate injectable suspension in a single dose vial in the US market.
Lynparza from AstraZeneca and MSD approved in Japan for high-risk early breast cancer
The drug Lynparza (olaparib), manufactured by AstraZeneca and MSD, has received approval in Japan for the adjuvant treatment of patients with early-stage BRCA-mutated, HER2-negative breast cancer who are at high risk of recurrence.
Lupin and I'rom Pharma entered into licensing agreement in Japan for a Denosumab biosimilar
Lupin Limited has signed an exclusive licencing agreement with I’rom Group Co. Ltd, a Japanese pharmaceutical company and as part of the Agreement’s terms, will exclusively register, distribute, and market the biosimilar Denosumab in Japan.
J&J receives first nod for multiple myeloma bispecific to complement its own CAR-T offering
Teclistamab, a BCMAxCD3 bispecific antibody
from Johnson & Johnson, has received its first
global approval in Europe for the treatment of
multiple myeloma following at least three prior
therapies.
